Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)

66 articles with Tarveda Therapeutics (Fomerly Known As Blend Therapeutics)

• Tarveda Therapeutics Announces Data from Phase 2 Trial of PEN-221 to Be Presented at NANETS 2021 Multidisciplinary NET Virtual Symposium

  11/1/2021

  Tarveda Therapeutics, Inc., which it refers to as Pentarin® miniature drug conjugates, today announced that data from the Phase 2 clinical trial of PEN-221 will be presented at the North American Neuroendocrine Tumor Society (NANETS) 2021 Multidisciplinary NET Medical Virtual Symposium occurring November 3-6, 2021.

• Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

  10/13/2021

  Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Brian Roberts, President and Chief Executive Officer, will present virtually at the Solebury Trout/BMO Fall 2021 Private Company Showcase on Thursday, October 14.

• Tarveda Therapeutics Presents Promising Phase 2 Data of PEN-221 in Gastrointestinal Mid-gut Neuroendocrine Tumors

  6/4/2021

  Tarveda Therapeutics, Inc., today announced data from the gastrointestinal (GI) mid-gut neuroendocrine tumors (NETs) cohort of its Phase 2 clinical trial of PEN-221, presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting.

• Tarveda Therapeutics to Present Data from Phase 2 Study of PEN-221 at 2021 ASCO Annual Meeting

  5/20/2021

  Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that the company will present data from its Phase 2 clinical trial of PEN-221 at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting occurring virtually June 4-8, 2021.

• 

  BioSpace Movers & Shakers, Oct. 2

  10/2/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
• 

  Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs

  8/6/2020

  Tarveda Therapeutics is advancing its miniature drug conjugates into Phase IIa trials, using a platform that combines the best aspects of small molecules and antibody drug conjugates while addressing their deficiencies.

• Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors

  8/4/2020

  Study published in Molecular Cancer Therapeutics HSP90 targeting drives high tumor uptake and retention of a pan-PI3K inhibitor payload Lead conjugate shows xenograft efficacy superior to non-targeted pan-PI3K inhibitor Tumor targeting and payload masking prevent hyperglycemia seen with other PI3Kα inhibitors

• Tarveda Therapeutics to Present at Upcoming Conferences

  7/30/2020

  Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, Chief Executive Officer, will present at the LifeSci Partners Private Healthcare Company Virtual Summer Symposium, occurring August 4-5, 2020. Mr. Fromkin will also participate in

• Tarveda Therapeutics Reports Complete Data from Phase 1 Portion of Phase 1/2a Study of PEN-866 to be Presented at the ASCO20 Virtual Scientific Program

  5/13/2020

  Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced the complete data from the Phase 1 dose escalation portion of a Phase 1/2a study of PEN-866 in advanced solid tumor malignancies

• Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

  4/27/2020

  Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugate

• Tarveda Therapeutics to Present Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting

  4/21/2020

  Tarveda Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin ® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the company will present data from its first in human study of PEN-866 at the 2020 American Association for Cancer Resear

• Tarveda Therapeutics Provides Update on Proposed Merger with Organovo

  4/7/2020

  Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, today announced that the proposed merger agreement with Organovo Holdings, Inc.

• Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics

  4/2/2020

  Believes Stockholders Sent a Loud and Clear Message at Special Meeting That They Oppose This Value-Destructive Combination

• Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders

  3/23/2020

  Believes the Board, Which Has Presided Over Significant Value Destruction in Recent Years, Has Asked Stockholders to Take an Unnecessary Risk Without Offering a Compelling Rationale

• Tarveda Therapeutics and SciClone Pharmaceuticals International Establish Licensing Agreement for PEN-866 in Greater China

  3/19/2020

  Tarveda Therapeutics, Inc. (“Tarveda”), a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies, and SciClone Pharmaceuticals International Ltd., (“SciClone”) today announced that they have entered into a licensing agreement for PEN-866,

• Tarveda Therapeutics to Present at the Cowen & Company 40th Annual Health Care Conference

  2/25/2020

  Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Drew Fromkin, President and Chief Executive Officer, will present at the Cowen & Company 40th Annual Health Care Conference,

• The Case Against Tarveda: An Open Letter to Organovo Shareholders

  1/21/2020

  Organovo, pointing to hurdles and timeline changes in the development of its human liver tissue for transplant, announced in August 2019 that it would seek strategic alternatives.

• Tarveda Therapeutics to Present at the 2020 Biotech Showcase

  1/8/2020

  Tarveda Therapeutics, Inc. announced that Drew Fromkin, President and Chief Executive Officer, will present at the 2020 Biotech Showcase, occurring January 13-15, 2020 at the Hilton Union Square in San Francisco, CA.

• Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement

  12/16/2019

  Organovo Holdings, Inc. (“Organovo”) (Nasdaq: ONVO) and Tarveda Therapeutics, Inc. (“Tarveda”), a privately-held, clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, today announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction.

• Tarveda Therapeutics Publishes Results of Preclinical Studies Evaluating PEN-221 as a Treatment for Small Cell Lung Cancer in Molecular Cancer Therapeutics

  10/24/2019

  Tarveda Therapeutics®, Inc., a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective precision oncology medicines for the treatment of patients with a wide range of solid tumor malignancies, today announced the publication of several preclinical studies evaluating PEN-221 as a novel therapeutic for the treatment of small cell lung cancer (SCLC).